<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63673">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01790737</url>
  </required_header>
  <id_info>
    <org_study_id>KUH5101424</org_study_id>
    <secondary_id>2012-001051-39</secondary_id>
    <nct_id>NCT01790737</nct_id>
  </id_info>
  <brief_title>First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02</brief_title>
  <acronym>FMG-MM02</acronym>
  <official_title>A Prospective Phase II Study to Assess Immunophenotypic Remission After 3-drug Induction Followed by Randomized Stem Cell Mobilization, Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mikkeli Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kymenlaakso Central Hospital Kotka Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jyväskylä Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seinajoki Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paijat-Hame Hospital District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital of Kanta-Hame</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Satakunta Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kainuu and Länsi-Pohja Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kuopio University Hospital</source>
  <oversight_info>
    <authority>Finland: Finnish Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determinate the efficacy and safety of the 3-drug induction
      treatment (RVD; lenalidomide plus bortezomib plus dexamethasone)followed by randomized
      autologous stem cell mobilization, autologous stem cell transplantation and lenalidomide
      maintenance. Primary endpoint is the  immunophenotypic remission rate.During the randomized
      mobilization phase two active comparator arms Cyclophosphamide (CY)2g/m2 +
      Granylocyte-colony stimulating factor)G-CSF vrs G-CSF will be compared regarding efficacy,
      costs and safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Immunophenotypic response</measure>
    <time_frame>Change from the start of induction treatment at 3 months, change from the start of induction at 6 months, at 9 months, at 12 months,  at 16 months,  at 20 months, at 24 moths</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Response will be measured by International Myeloma Working Group (IMWG) guidelines, and if the response is stringent CR and immunophenotypic remission, those patients will be followed also by allele-spesific oligonucleotide-polymerase chain reaction assay (ASO-PCR) to find out molecular remission rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of inclusion until the date of first documented progression or date of death from any cause whatever come first assessed up to laste patient 2 years on maintenance</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of pts collected with &gt; 3 x 10e6/kg CD34+ with &lt;/= 2 apheresis after mobilization with CY 2g/m2 + filgrastim (group A) or filgrastim alone (group B)</measure>
    <time_frame>Assessed up to 2 weeks from the start of mobilization</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclophosphamide plus filgrastim</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Filgrastim</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>A</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <arm_group_label>B</arm_group_label>
    <other_name>Filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  symptomatic, previously untreated International Stating System (ISS) 1-3 myeloma

          -  measurable disease

          -  WHO perf status 0-3

          -  eligible for ASCT

        Exclusion Criteria:

          -  previously treated

          -  peripheral neuropathy gr &gt;/= 2

          -  significant hepatic dysfunction

          -  severe cardiac dysfunction

          -  severe renal failure if not in dialysis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raija H Silvennoinen, MD</last_name>
    <phone>+358447176075</phone>
    <email>raija.silvennoinen@kuh.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esa Jantunen, MD,PhD</last_name>
    <phone>+358447176075</phone>
    <email>esa.jantunen@kuh.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <state>North Savo</state>
        <zip>70200</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raija H Silvennoinen, MD</last_name>
      <phone>+358447176075</phone>
      <email>raija.silvennoinen@kuh.fi</email>
    </contact>
    <contact_backup>
      <last_name>Esa Jantunen, MD, PhD</last_name>
      <phone>+358447172569</phone>
      <email>esa.jantunen@kuh.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Raija H Silvennoinen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esa Jantunen, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tapio Nousiainen, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taru Kuittinen, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marja Pyörälä, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 12, 2013</lastchanged_date>
  <firstreceived_date>February 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myeloma, stem cell mobilization, autologous stem cell transplantation</keyword>
  <keyword>induction treatment, maintenance treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
